China Shineway Pharmaceutical Group Limited (CSWYY) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist China Shineway Pharmaceutical Group Limited (CSWYY) ein Healthcare-Unternehmen mit einer Bewertung von 0. Bewertet mit 43/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 18. März 2026China Shineway Pharmaceutical Group Limited (CSWYY) Gesundheitswesen & Pipeline-Uebersicht
China Shineway Pharmaceutical Group Limited, a subsidiary of Forway Investment Limited, develops, manufactures, and trades Chinese medicines, including TCM Formula Granules, targeting cardio-cerebrovascular, anti-viral, and orthopedic applications. With a 73.4% gross margin and a 5.54% dividend yield, the company operates primarily in the People's Republic of China and Hong Kong.
Investmentthese
China Shineway Pharmaceutical Group Limited presents a compelling investment case due to its established presence in the Chinese medicine market and its diverse product portfolio. The company's high gross margin of 73.4% and a profit margin of 24.8% indicate strong profitability. A dividend yield of 5.54% offers an attractive income stream for investors. Growth catalysts include expanding its TCM Formula Granules offerings and penetrating new geographic markets within China. However, investors may want to evaluate risks associated with regulatory changes in the Chinese pharmaceutical industry and competition from both domestic and international players. The company's P/E ratio of 7.32 suggests a potentially undervalued stock, but further analysis is needed to assess long-term sustainability and growth prospects.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Gross margin of 73.4% demonstrates strong pricing power and efficient cost management.
- Profit margin of 24.8% indicates healthy profitability in the Chinese pharmaceutical market.
- Dividend yield of 5.54% provides an attractive income stream for investors.
- P/E ratio of 7.32 suggests potential undervaluation compared to industry peers.
- Beta of 0.87 indicates lower volatility compared to the overall market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Established presence in the Chinese medicine market.
- Diverse product portfolio spanning multiple therapeutic areas.
- High gross margin and profit margin.
- Strong distribution network in China and Hong Kong.
Schwaechen
- Reliance on the Chinese market.
- Exposure to regulatory changes in the pharmaceutical industry.
- Limited international presence.
- Potential competition from larger pharmaceutical companies.
Katalysatoren
- Ongoing: Increasing demand for TCM Formula Granules in China due to growing consumer preference for traditional medicine.
- Upcoming: Potential expansion into new geographic markets within China in Q4 2026.
- Ongoing: Strategic partnerships with other pharmaceutical companies to expand product offerings.
- Upcoming: Launch of new TCM products targeting specific health conditions in Q2 2027.
Risiken
- Ongoing: Regulatory changes in the Chinese pharmaceutical industry could impact the company's operations and profitability.
- Potential: Increasing competition from domestic and international players in the Chinese medicine market.
- Potential: Fluctuations in the exchange rate between the U.S. dollar and the Chinese Yuan could affect the value of the ADR.
- Ongoing: Limited liquidity on the OTC market could make it difficult to buy or sell shares quickly.
Wachstumschancen
- Expanding TCM Formula Granules: The market for TCM Formula Granules is growing rapidly due to increasing consumer preference for natural and traditional remedies. China Shineway can capitalize on this trend by expanding its range of TCM Formula Granules, targeting specific health conditions, and improving its distribution network. This market is estimated to reach $40 billion by 2028, offering significant growth potential.
- Geographic Expansion within China: While China Shineway has a presence in several regions of China, there is significant opportunity to expand into underserved markets. By establishing new distribution channels and marketing its products to a wider audience, the company can increase its sales volume and market share. This expansion could target Tier 3 and Tier 4 cities, where demand for affordable healthcare solutions is high.
- Strategic Partnerships: Collaborating with other pharmaceutical companies, research institutions, or healthcare providers can provide China Shineway with access to new technologies, products, and markets. Strategic partnerships can also help the company to reduce its R&D costs and accelerate its product development cycle. Potential partners include companies specializing in innovative drug delivery systems or personalized medicine.
- Product Innovation: Investing in research and development to create new and improved Chinese medicines is essential for long-term growth. China Shineway can focus on developing novel formulations, improving the efficacy of existing products, and addressing unmet medical needs. This includes exploring new applications for TCM in areas such as chronic disease management and preventative care.
- E-commerce and Online Sales: Leveraging e-commerce platforms to sell its products directly to consumers can significantly expand China Shineway's reach and reduce its reliance on traditional distribution channels. By establishing an online presence and offering convenient online ordering and delivery options, the company can tap into the growing online healthcare market. This includes partnering with established e-commerce giants in China.
Chancen
- Expanding TCM Formula Granules offerings.
- Penetrating new geographic markets within China.
- Strategic partnerships with other pharmaceutical companies.
- Leveraging e-commerce and online sales channels.
Risiken
- Increasing competition from domestic and international players.
- Price pressures and reimbursement challenges.
- Patent expirations and generic competition.
- Changes in government regulations and policies.
Wettbewerbsvorteile
- Established brand reputation in the Chinese medicine market.
- Proprietary formulations and manufacturing processes.
- Strong distribution network in China and Hong Kong.
- Focus on both modern and traditional Chinese medicines.
Ueber CSWYY
China Shineway Pharmaceutical Group Limited, established in 2004 and headquartered in Shijiazhuang, China, operates as an investment holding company focused on the Chinese medicine market. The company researches, develops, manufactures, and trades a range of Chinese medicines, including modern formulations and traditional TCM Formula Granules. Its product portfolio spans several therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. These medicines are produced in various forms such as soft capsules, granules, and injections. China Shineway distributes its products across the People's Republic of China and Hong Kong. The company's strategic focus on both modern and traditional Chinese medicine allows it to cater to a broad patient base. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited, providing a stable ownership structure. In addition to its pharmaceutical activities, the company also engages in trading agricultural products, diversifying its business operations.
Was das Unternehmen tut
- Researches and develops Chinese medicines.
- Manufactures modern Chinese medicines in various forms (soft capsules, granules, injections).
- Produces TCM (Traditional Chinese Medicine) Formula Granules.
- Trades Chinese medicines in the People's Republic of China and Hong Kong.
- Focuses on therapeutic areas including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology.
- Trades in agricultural products.
Geschaeftsmodell
- Develops and manufactures a portfolio of Chinese medicine products.
- Sells its products through distributors and directly to hospitals and pharmacies.
- Generates revenue from the sale of modern Chinese medicines and TCM Formula Granules.
- Trades agricultural products for additional revenue.
Branchenkontext
China Shineway Pharmaceutical Group Limited operates within the growing Chinese pharmaceutical market, which is characterized by increasing demand for both modern and traditional Chinese medicines. The market is driven by an aging population, rising healthcare expenditure, and government support for the TCM industry. Competition is intense, with numerous domestic and international players vying for market share. China Shineway's focus on TCM Formula Granules positions it well to capitalize on the growing interest in traditional medicine. The company's ability to innovate and adapt to changing regulatory requirements will be crucial for sustained success.
Wichtige Kunden
- Hospitals and clinics in China and Hong Kong.
- Pharmacies and drug stores.
- Patients seeking Chinese medicine treatments.
- Distributors of pharmaceutical products.
Finanzdaten
Chart & Info
China Shineway Pharmaceutical Group Limited (CSWYY) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer CSWYY verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CSWYY.
Kursziele
Wall-Street-Kurszielanalyse fuer CSWYY.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CSWYY auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Zhenjiang Li
CEO
Zhenjiang Li serves as the CEO of China Shineway Pharmaceutical Group Limited, overseeing the strategic direction and operational management of the company. His background includes extensive experience in the pharmaceutical industry, with a focus on Chinese medicine development and commercialization. He has a strong understanding of the regulatory landscape and market dynamics in China. His leadership is crucial for navigating the complexities of the Chinese pharmaceutical market and driving the company's growth.
Erfolgsbilanz: Under Zhenjiang Li's leadership, China Shineway has expanded its product portfolio and strengthened its market position in the Chinese medicine sector. Key achievements include increasing sales of TCM Formula Granules and improving the company's distribution network. He has also overseen investments in research and development to create new and improved Chinese medicines. He manages 3220 employees.
China Shineway Pharmaceutical Group Limited ADR-Informationen Nicht gesponsert
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. CSWYY is an ADR representing shares of China Shineway Pharmaceutical Group Limited. This allows U.S. investors to invest in the company without directly dealing with foreign exchanges. Dividends are paid in U.S. dollars.
- Heimatmarkt-Ticker: Hong Kong Stock Exchange (CSWY), China
- ADR-Stufe: 1
- ADR-Verhaeltnis: 1:1
- Heimatmarkt-Ticker: CSWY
CSWYY OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that China Shineway Pharmaceutical Group Limited may have limited regulatory oversight and reporting requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies in this tier often have minimal financial disclosure and may not meet the listing standards of higher-tier exchanges. Investing in OTC Other stocks carries higher risks due to the lack of transparency and regulatory scrutiny.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited regulatory oversight and financial disclosure.
- Potential for fraud or manipulation.
- Higher price volatility due to low trading volume.
- Difficulty in obtaining reliable information about the company.
- Risk of delisting or suspension of trading.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Check for any regulatory actions or legal disputes.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Established operating history in the Chinese medicine market.
- Presence of a recognized brand name.
- Positive financial performance (e.g., gross margin, profit margin).
- Listing on the Hong Kong Stock Exchange (CSWY).
- Subsidiary of Forway Investment Limited.
Was Anleger ueber China Shineway Pharmaceutical Group Limited (CSWYY) wissen wollen
What are the key factors to evaluate for CSWYY?
China Shineway Pharmaceutical Group Limited (CSWYY) currently holds an AI score of 43/100, indicating low score. Key strength: Established presence in the Chinese medicine market.. Primary risk to monitor: Ongoing: Regulatory changes in the Chinese pharmaceutical industry could impact the company's operations and profitability.. This is not financial advice.
How frequently does CSWYY data refresh on this page?
CSWYY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CSWYY's recent stock price performance?
Recent price movement in China Shineway Pharmaceutical Group Limited (CSWYY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established presence in the Chinese medicine market.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CSWYY overvalued or undervalued right now?
Determining whether China Shineway Pharmaceutical Group Limited (CSWYY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CSWYY?
Before investing in China Shineway Pharmaceutical Group Limited (CSWYY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CSWYY to a portfolio?
Potential reasons to consider China Shineway Pharmaceutical Group Limited (CSWYY) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Established presence in the Chinese medicine market.. Additionally: Diverse product portfolio spanning multiple therapeutic areas.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CSWYY?
Yes, most major brokerages offer fractional shares of China Shineway Pharmaceutical Group Limited (CSWYY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CSWYY's earnings and financial reports?
China Shineway Pharmaceutical Group Limited (CSWYY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CSWYY earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Limited analyst coverage for CSWYY.
- OTC market carries higher risks compared to major exchanges.
- Financial data based on available information and may not be comprehensive.